Last reviewed 2026-04-23 · How we verify

botulinum toxin A + ropivacaïne

Botulinum toxin A blocks the release of acetylcholine, a neurotransmitter that causes muscle contraction, while ropivacaine is a local anesthetic that blocks sodium channels to prevent nerve impulses.

Botulinum toxin A blocks the release of acetylcholine, a neurotransmitter that causes muscle contraction, while ropivacaine is a local anesthetic that blocks sodium channels to prevent nerve impulses. Used for Chronic pain management, Muscle spasticity.

At a glance

Mechanism of action

Botulinum toxin A works by cleaving the SNARE complex, preventing the release of acetylcholine from the presynaptic neuron. This results in a reduction in muscle contraction. Ropivacaine, on the other hand, works by blocking sodium channels, which prevents the initiation and transmission of nerve impulses, leading to a loss of sensation and muscle relaxation.

Approved indications

• Chronic pain management
• Muscle spasticity

Common side effects

• Numbness
• Dizziness
• Headache

Key clinical trials

• Multicenter Randomized Double-blind Study Evaluating the Effects of Botulinum Toxin A Associated With ropivacaïne Versus ropivacaïne Alone in the Treatment of the Myofascial Pelviperineal Pain (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• botulinum toxin A + ropivacaïne CI brief — competitive landscape report
• botulinum toxin A + ropivacaïne updates RSS · CI watch RSS
• Nantes University Hospital portfolio CI